Versant Capital Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Versant Capital Management’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5,000	Closed	-$12K	–	1705
2022 Q1	$12K	Sell	5,000 -5,000	-50%	-$15.6K	﹤0.01%	649
2021 Q4	$47K	Buy	+10,000	New	+$62.1K	0.02%	259
2020 Q3	–	Sell	-125	Closed	–	–	1568
2020 Q2	$0	Buy	+125	New	+$479	﹤0.01%	1626

Other funds holding SRNE

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Versant Capital Management's SRNE Position: Q2 2022 in Review

Versant Capital Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2022, closing a stake of 5,000 shares — an estimated $12K sold.

Versant Capital Management first reported a position in SRNE in Q2 2020 and held it in 3 quarters. The position peaked at $47K in Q4 2021. 229 funds tracked by Wall St. Rank hold SRNE as of Q2 2022.

Versant Capital Management reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2022 after selling out during the quarter.
Versant Capital Management sold 5,000 Sorrento Therapeutics, Inc. shares in Q2 2022, an estimated $12K.
Versant Capital Management first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 3 quarters.
Versant Capital Management's Sorrento Therapeutics, Inc. position peaked at $47K in Q4 2021.
229 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2022.

Based on Versant Capital Management's 13F filing for Q2 2022, filed 2 Aug 2022.